
SWOG S1815 Shows Need for Subgroup-Specific Triplet Chemotherapy Assessment in Biliary Tract Cancer
Signals of efficacy observed with the addition of nab-paclitaxel (Abraxane) to gemcitabine and cisplatin (GAP) in select subgroups of patients with newly diagnosed advanced biliary tract cancers reinforce the biological heterogeneity of these malignancies …